Cargando…
A Novel Synthetic Microtubule Inhibitor, MPT0B214 Exhibits Antitumor Activity in Human Tumor Cells through Mitochondria-Dependent Intrinsic Pathway
Agents that interfere with mitotic progression by disturbing microtubule dynamics are commonly used for cancer treatment. Previously, a series of aroylquinolone regioisomers as novel microtubule inhibitors were discovered. One of these new compounds, MPT0B214 inhibited tubulin polymerization through...
Autores principales: | Chiang, Nai-Jung, Lin, Ching-I, Liou, Jing-Ping, Kuo, Ching-Chuan, Chang, Chi-Yen, Chen, Li-Tzong, Chang, Jang-Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595215/ https://www.ncbi.nlm.nih.gov/pubmed/23554962 http://dx.doi.org/10.1371/journal.pone.0058953 |
Ejemplares similares
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
por: Tsai, I-Ting, et al.
Publicado: (2018) -
MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma
por: Peng, Hsuan-Yu, et al.
Publicado: (2016) -
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib
por: Tsai, A-C, et al.
Publicado: (2014) -
Is the Low-Thalidomide Dose MPT Regimen Beneficial?
por: Min, Chang-Ki
Publicado: (2011) -
Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis
por: Huang, Yen-Chia, et al.
Publicado: (2015)